2023 Fiscal Year Final Research Report

Continuous study focusing on artifactless marker in prostate cancer men undergoing external beam radiation therapy

Research Project

PDF

Project/Area Number	21K09352
Research Category	Grant-in-Aid for Scientific Research (C)
Allocation Type	Multi-year Fund
Section	一般
Review Section	Basic Section 56030:Urology-related
Research Institution	Kyoto Prefectural University of Medicine
Principal Investigator	Okihara Koji 京都府立医科大学, 医学(系)研究科(研究院), 特任教授 (80285270)
Co-Investigator(Kenkyū-buntansha)	藤原敦子京都府立医科大学, 医学(系)研究科(研究院), 講師 (20457980) 上田崇京都府立医科大学, 医学(系)研究科(研究院), 助教 (50601598) 相部則博京都府立医科大学, 医学(系)研究科(研究院), 助教 (50739240) 浮村理京都府立医科大学, 医学(系)研究科(研究院), 教授 (70275220) 白石匠京都府立医科大学, 医学(系)研究科(研究院), 助教 (70405314) 鈴木弦京都府立医科大学, 医学(系)研究科(研究院), 准教授 (80279182) 石田博万京都府立医科大学, 医学(系)研究科(研究院), 客員講師 (80405315) 本郷文弥京都府立医科大学, 医学(系)研究科(研究院), 准教授 (80291798) 内藤泰行京都府立医科大学, 医学(系)研究科(研究院), 講師 (50405312) 山田剛司京都府立医科大学, 医学(系)研究科(研究院), 助教 (20453095)
Project Period (FY)	2021-04-01 – 2024-03-31
Keywords	前立腺癌 / 放射線治療 / 局所療法 / マーカー / アーチファクト
Outline of Final Research Achievements	Using the artifact-less marker developed in previous research, we conducted a non-clinical trial for external beam radiation therapy and examined its usefulness. First, a pathological specimen of the same marker was used to confirm that there was no crushing or migration associated with the puncture. Next, we manufactured a total of six types of markers, combining gold single agent, platinum single agent composition, and pitch interval, and measured the acoustic impedance of single gold and single platinum. It was found that the acoustic difference was small. Next, an MRI artifact test was conducted using the same six types of markers, proving the superiority of the gold/platinum alloy coil. As the final step, we published the research content and created an experimental protocol using Cadaver.
Free Research Field	泌尿器科学　放射線腫瘍学
Academic Significance and Societal Importance of the Research Achievements	前立腺癌診断に頻用されるMRI・超音波・CT全てでアーチファクトレスなマーカは本開発品のみであり、日本発のシーズに基づく本マーカの製品化が、世界的な前立腺癌の治療（監視療法や放射線治療）の変革に不可欠なツールとなる。